Protagonist Therapeutics, Inc. (PTGX)

Over the past six months, Protagonist Therapeutics' stock price has been impacted by several significant events. The company reported strong Q1 2026 earnings, exceeding analysts' expectations. Protagonist exercised its U.S. opt-out right on rusfertide, triggering a $200 million payment. Johnson & Johnson received FDA approval for Icotyde (icotrokinra). Following these positive developments, several research firms upgraded their ratings and increased price targets for PTGX. In the past three months, Protagonist Therapeutics insiders have sold more of their company's stock than they have bought. The company's shares have risen more than 120% in the past year.

As a clinical-stage biopharmaceutical company, Protagonist Therapeutics, Inc. does not experience traditional demand seasonality for its products and services. The company's revenue is primarily derived from collaboration agreements, milestone payments, and licensing activities related to its drug candidates. Therefore, the demand for its products and services is not subject to seasonal fluctuations but rather to the progress of its clinical trials, regulatory approvals, and strategic partnerships.

Protagonist Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing peptide-based therapeutic drugs. The company operates in the Healthcare sector, specifically in the Biotechnology and Medical Research industry, utilizing a proprietary technology platform to create peptide-based new chemical entities (NCEs) aimed at addressing unmet medical needs. The company's clinical programs primarily focus on hematology and blood disorders, and inflammatory and immunomodulatory diseases. Key product candidates include Rusfertide (PTG-300), Icotrokinra (JNJ-2113), PN-943, PN-881, PN-477 and PN-458, PN-47, and PN-8047.

Protagonist Therapeutics, Inc. is headquartered in Newark, California, USA, and has an innovation hub in Brisbane, Australia. While its operating footprint is concentrated in the United States and Australia, its development and commercial reach are global through strategic partnerships.

Protagonist Therapeutics has maintained a positive brand reputation over the past year, largely bolstered by significant clinical and regulatory achievements. The FDA approval of Icotyde (icotrokinra) for moderate-to-severe plaque psoriasis has been a key positive event. The company emphasizes its commitment to patients, employees, and the life sciences community and maintains a corporate compliance program.

Protagonist Therapeutics, Inc. has a diverse ownership structure, with approximately 98.63% of the stock held by institutions. Major institutional owners include BlackRock, Inc., Farallon Capital Management LLC, Vanguard Group Inc., RTW Investments, LP, State Street Corp., Wellington Management Group LLP, UBS Group AG, Janus Henderson Group Plc, Johnson & Johnson and Invesco Ltd. Julie Papanek is the largest individual shareholder, owning 2.45 million shares representing 3.84% of the company. Insiders hold about 4.90% of the stock.